New Gene-Targeting shot shows promise for cholesterol control
NCT ID NCT07412080
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a single injection of EDP167, a new drug that uses RNA technology to lower certain blood fats. The study included 40 healthy adults and people with mild dyslipidemia (abnormal cholesterol levels). The main goal was to check the drug's safety and how the body processes it, not to prove it works as a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT MALE AND FEMALE VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Breathe deep: new study reveals how slow breathing calms your Body's nerves
- New drug ORX489 put to the test in healthy adults
- Exercise before surgery: could ReHIIT boost recovery for bowel cancer patients?
- Healthy volunteers help Fine-Tune experimental drug vonafexor
- New implant for addiction treatment put to the test in healthy volunteers
- Healthy volunteers test generic vs. Brand-Name water pill